Stem definition | Drug id | CAS RN |
---|---|---|
2286 | 60-87-7 |
Dose | Unit | Route |
---|---|---|
25 | mg | O |
25 | mg | P |
25 | mg | R |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 5.03 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 14 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 14 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.09 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 14 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
March 29, 1951 | FDA | DELCOR ASSET CORP |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intentional self-injury | 6218.26 | 10.17 | 2042 | 75748 | 23242 | 53248034 |
Intentional overdose | 5068.65 | 10.17 | 2294 | 75496 | 64911 | 53206365 |
Akathisia | 499.88 | 10.17 | 246 | 77544 | 8325 | 53262951 |
Tachycardia | 382.13 | 10.17 | 616 | 77174 | 107596 | 53163680 |
Depressed level of consciousness | 369.99 | 10.17 | 426 | 77364 | 54002 | 53217274 |
Mydriasis | 271.45 | 10.17 | 182 | 77608 | 11144 | 53260132 |
Drug ineffective | 268.50 | 10.17 | 491 | 77299 | 816754 | 52454522 |
Cholecystitis chronic | 264.11 | 10.17 | 174 | 77616 | 10344 | 53260932 |
Rheumatoid arthritis | 238.11 | 10.17 | 81 | 77709 | 314450 | 52956826 |
Toxicity to various agents | 187.92 | 10.17 | 724 | 77066 | 218874 | 53052402 |
Anxiety | 171.10 | 10.17 | 652 | 77138 | 196052 | 53075224 |
Contraindicated product administered | 161.19 | 10.17 | 9 | 77781 | 135620 | 53135656 |
Drug abuse | 146.01 | 10.17 | 306 | 77484 | 65220 | 53206056 |
Synovitis | 128.68 | 10.17 | 7 | 77783 | 107886 | 53163390 |
Nausea | 128.07 | 10.17 | 1670 | 76120 | 754421 | 52516855 |
Suicide attempt | 123.07 | 10.17 | 266 | 77524 | 57902 | 53213374 |
Hallucination | 120.60 | 10.17 | 252 | 77538 | 53586 | 53217690 |
Treatment failure | 120.46 | 10.17 | 21 | 77769 | 128382 | 53142894 |
Joint swelling | 113.47 | 10.17 | 105 | 77685 | 234533 | 53036743 |
Drug intolerance | 112.99 | 10.17 | 81 | 77709 | 205412 | 53065864 |
Off label use | 110.13 | 10.17 | 339 | 77451 | 471873 | 52799403 |
Glossodynia | 109.53 | 10.17 | 10 | 77780 | 100281 | 53170995 |
Vomiting | 109.13 | 10.17 | 1155 | 76635 | 495984 | 52775292 |
Hand deformity | 106.09 | 10.17 | 4 | 77786 | 84845 | 53186431 |
Poisoning | 103.56 | 10.17 | 114 | 77676 | 13736 | 53257540 |
Completed suicide | 103.14 | 10.17 | 437 | 77353 | 137764 | 53133512 |
Somnolence | 99.68 | 10.17 | 496 | 77294 | 167238 | 53104038 |
Injury | 92.12 | 10.17 | 219 | 77571 | 50752 | 53220524 |
Biliary dyskinesia | 85.15 | 10.17 | 52 | 77738 | 2705 | 53268571 |
Gallbladder disorder | 84.84 | 10.17 | 118 | 77672 | 18047 | 53253229 |
Agitation | 83.26 | 10.17 | 230 | 77560 | 58396 | 53212880 |
Sinus tachycardia | 80.05 | 10.17 | 132 | 77658 | 23440 | 53247836 |
Arthropathy | 78.71 | 10.17 | 55 | 77735 | 141398 | 53129878 |
Systemic lupus erythematosus | 76.31 | 10.17 | 44 | 77746 | 125370 | 53145906 |
Gallbladder injury | 76.02 | 10.17 | 38 | 77752 | 1329 | 53269947 |
Emotional distress | 75.56 | 10.17 | 154 | 77636 | 32163 | 53239113 |
Migraine | 75.12 | 10.17 | 273 | 77517 | 80144 | 53191132 |
Therapeutic product effect decreased | 72.40 | 10.17 | 47 | 77743 | 125608 | 53145668 |
Pericarditis | 68.79 | 10.17 | 7 | 77783 | 64399 | 53206877 |
Infusion related reaction | 66.09 | 10.17 | 78 | 77712 | 155879 | 53115397 |
Abdominal discomfort | 63.32 | 10.17 | 143 | 77647 | 220919 | 53050357 |
Hepatic enzyme increased | 61.50 | 10.17 | 56 | 77734 | 126139 | 53145137 |
Wound | 58.78 | 10.17 | 30 | 77760 | 91527 | 53179749 |
Arthralgia | 56.73 | 10.17 | 392 | 77398 | 439391 | 52831885 |
Accidental overdose | 55.82 | 10.17 | 107 | 77683 | 21372 | 53249904 |
Rash | 55.46 | 10.17 | 402 | 77388 | 445789 | 52825487 |
Serotonin syndrome | 53.82 | 10.17 | 119 | 77671 | 26287 | 53244989 |
Snoring | 52.80 | 10.17 | 44 | 77746 | 3748 | 53267528 |
Cholelithiasis | 51.64 | 10.17 | 154 | 77636 | 40810 | 53230466 |
Alopecia | 51.31 | 10.17 | 173 | 77617 | 234410 | 53036866 |
Muscle twitching | 50.49 | 10.17 | 88 | 77702 | 16338 | 53254938 |
Product use issue | 49.87 | 10.17 | 79 | 77711 | 139505 | 53131771 |
Therapeutic product effect incomplete | 49.32 | 10.17 | 37 | 77753 | 91747 | 53179529 |
Respiratory arrest | 49.01 | 10.17 | 133 | 77657 | 33407 | 53237869 |
Incoherent | 48.68 | 10.17 | 46 | 77744 | 4626 | 53266650 |
Accidental death | 46.27 | 10.17 | 30 | 77760 | 1734 | 53269542 |
Opisthotonus | 46.20 | 10.17 | 18 | 77772 | 341 | 53270935 |
Dependence | 45.60 | 10.17 | 32 | 77758 | 2109 | 53269167 |
Formication | 44.61 | 10.17 | 41 | 77749 | 3980 | 53267296 |
Pulmonary haemorrhage neonatal | 42.83 | 10.17 | 10 | 77780 | 25 | 53271251 |
Nasopharyngitis | 42.59 | 10.17 | 141 | 77649 | 192154 | 53079122 |
Swelling | 42.41 | 10.17 | 140 | 77650 | 190965 | 53080311 |
Mental status changes | 40.95 | 10.17 | 139 | 77651 | 39432 | 53231844 |
Lethargy | 40.82 | 10.17 | 171 | 77619 | 53589 | 53217687 |
Lower respiratory tract infection | 40.15 | 10.17 | 44 | 77746 | 90937 | 53180339 |
Loss of consciousness | 39.17 | 10.17 | 293 | 77497 | 113919 | 53157357 |
Hereditary angioedema | 37.57 | 10.17 | 46 | 77744 | 6207 | 53265069 |
Pupillary reflex impaired | 37.05 | 10.17 | 28 | 77762 | 2071 | 53269205 |
Suicidal ideation | 36.62 | 10.17 | 180 | 77610 | 60331 | 53210945 |
Infection | 36.28 | 10.17 | 129 | 77661 | 172076 | 53099200 |
Cardiac failure | 36.27 | 10.17 | 43 | 77747 | 85801 | 53185475 |
Abdominal pain | 35.95 | 10.17 | 548 | 77242 | 255355 | 53015921 |
Exposure via ingestion | 35.74 | 10.17 | 33 | 77757 | 3222 | 53268054 |
Helicobacter infection | 35.31 | 10.17 | 7 | 77783 | 39062 | 53232214 |
Dysarthria | 33.95 | 10.17 | 133 | 77657 | 40435 | 53230841 |
Maternal exposure during pregnancy | 33.85 | 10.17 | 115 | 77675 | 155524 | 53115752 |
Hypersensitivity | 32.71 | 10.17 | 177 | 77613 | 210488 | 53060788 |
Deep vein thrombosis | 32.67 | 10.17 | 220 | 77570 | 82693 | 53188583 |
Muscle injury | 32.40 | 10.17 | 3 | 77787 | 29763 | 53241513 |
Drug hypersensitivity | 32.39 | 10.17 | 555 | 77235 | 264687 | 53006589 |
Discomfort | 32.26 | 10.17 | 56 | 77734 | 95416 | 53175860 |
Peripheral swelling | 32.10 | 10.17 | 173 | 77617 | 205935 | 53065341 |
Impaired healing | 31.85 | 10.17 | 28 | 77762 | 64177 | 53207099 |
Electrocardiogram QRS complex shortened | 31.79 | 10.17 | 15 | 77775 | 461 | 53270815 |
Congenital tricuspid valve incompetence | 31.76 | 10.17 | 10 | 77780 | 97 | 53271179 |
Depression | 30.49 | 10.17 | 404 | 77386 | 182648 | 53088628 |
Folliculitis | 30.13 | 10.17 | 5 | 77785 | 31704 | 53239572 |
C-reactive protein increased | 29.77 | 10.17 | 33 | 77757 | 67853 | 53203423 |
Drug reaction with eosinophilia and systemic symptoms | 29.38 | 10.17 | 6 | 77784 | 32794 | 53238482 |
General physical health deterioration | 29.03 | 10.17 | 113 | 77677 | 146829 | 53124447 |
Newborn persistent pulmonary hypertension | 28.51 | 10.17 | 10 | 77780 | 139 | 53271137 |
Neonatal hypotension | 28.38 | 10.17 | 10 | 77780 | 141 | 53271135 |
Electrocardiogram QT prolonged | 28.10 | 10.17 | 159 | 77631 | 56244 | 53215032 |
Anticholinergic syndrome | 27.78 | 10.17 | 23 | 77767 | 1941 | 53269335 |
Drug screen positive | 27.45 | 10.17 | 31 | 77759 | 3841 | 53267435 |
Drug abuser | 27.19 | 10.17 | 28 | 77762 | 3125 | 53268151 |
Overdose | 27.16 | 10.17 | 258 | 77532 | 107478 | 53163798 |
Dehydration | 26.53 | 10.17 | 368 | 77422 | 168042 | 53103234 |
Cardiac arrest | 25.99 | 10.17 | 229 | 77561 | 93438 | 53177838 |
Neonatal respiratory failure | 24.81 | 10.17 | 10 | 77780 | 208 | 53271068 |
Restlessness | 24.25 | 10.17 | 93 | 77697 | 27994 | 53243282 |
Product counterfeit | 24.22 | 10.17 | 9 | 77781 | 149 | 53271127 |
Cholestasis | 24.20 | 10.17 | 6 | 77784 | 28689 | 53242587 |
Impaired gastric emptying | 23.43 | 10.17 | 45 | 77745 | 8998 | 53262278 |
Renal impairment | 22.93 | 10.17 | 55 | 77735 | 83263 | 53188013 |
Somatic delusion | 22.72 | 10.17 | 13 | 77777 | 599 | 53270677 |
Cardio-respiratory arrest | 22.60 | 10.17 | 155 | 77635 | 58603 | 53212673 |
Mobility decreased | 22.08 | 10.17 | 49 | 77741 | 76222 | 53195054 |
Neutropenia | 21.90 | 10.17 | 139 | 77651 | 159046 | 53112230 |
Cholecystitis | 21.81 | 10.17 | 60 | 77730 | 15186 | 53256090 |
Hyperreflexia | 21.80 | 10.17 | 33 | 77757 | 5447 | 53265829 |
Gallbladder hypofunction | 21.35 | 10.17 | 12 | 77778 | 534 | 53270742 |
Gastrointestinal disorder | 21.31 | 10.17 | 64 | 77726 | 89940 | 53181336 |
Mental disorder | 21.28 | 10.17 | 81 | 77709 | 24295 | 53246981 |
Hypopnoea | 21.25 | 10.17 | 22 | 77768 | 2471 | 53268805 |
Arthritis | 20.01 | 10.17 | 63 | 77727 | 87235 | 53184041 |
Gallbladder cholesterolosis | 19.87 | 10.17 | 13 | 77777 | 763 | 53270513 |
Poor feeding infant | 19.66 | 10.17 | 9 | 77781 | 258 | 53271018 |
Fatigue | 18.99 | 10.17 | 1271 | 76519 | 729235 | 52542041 |
Drug withdrawal syndrome | 18.87 | 10.17 | 86 | 77704 | 27936 | 53243340 |
Device expulsion | 18.78 | 10.17 | 10 | 77780 | 29803 | 53241473 |
Cholecystectomy | 18.62 | 10.17 | 43 | 77747 | 9772 | 53261504 |
Acute kidney injury | 18.40 | 10.17 | 260 | 77530 | 253608 | 53017668 |
Pancreatitis chronic | 18.16 | 10.17 | 20 | 77770 | 2410 | 53268866 |
Hip arthroplasty | 18.07 | 10.17 | 9 | 77781 | 27853 | 53243423 |
Melaena | 18.02 | 10.17 | 10 | 77780 | 29119 | 53242157 |
Cholesterosis | 17.96 | 10.17 | 10 | 77780 | 437 | 53270839 |
Condition aggravated | 17.94 | 10.17 | 315 | 77475 | 296819 | 52974457 |
Therapeutic response decreased | 17.86 | 10.17 | 26 | 77764 | 47543 | 53223733 |
Pupil fixed | 17.86 | 10.17 | 17 | 77773 | 1725 | 53269551 |
Seizure | 17.63 | 10.17 | 276 | 77514 | 129233 | 53142043 |
Illness anxiety disorder | 17.57 | 10.17 | 7 | 77783 | 141 | 53271135 |
Hepatocellular injury | 17.55 | 10.17 | 11 | 77779 | 29975 | 53241301 |
Blood potassium decreased | 17.54 | 10.17 | 110 | 77680 | 40350 | 53230926 |
Atrial septal defect | 17.42 | 10.17 | 34 | 77756 | 6880 | 53264396 |
Coma blister | 17.26 | 10.17 | 7 | 77783 | 148 | 53271128 |
Drug resistance | 17.17 | 10.17 | 4 | 77786 | 19958 | 53251318 |
Helplessness | 17.04 | 10.17 | 8 | 77782 | 243 | 53271033 |
Blood pressure fluctuation | 16.96 | 10.17 | 16 | 77774 | 35454 | 53235822 |
Fall | 16.87 | 10.17 | 396 | 77394 | 358044 | 52913232 |
Red blood cell sedimentation rate increased | 16.83 | 10.17 | 10 | 77780 | 28047 | 53243229 |
Cytomegalovirus infection | 16.64 | 10.17 | 4 | 77786 | 19535 | 53251741 |
Biliary colic | 16.51 | 10.17 | 23 | 77767 | 3522 | 53267754 |
Miosis | 15.93 | 10.17 | 33 | 77757 | 6969 | 53264307 |
Hyponatraemia | 15.89 | 10.17 | 93 | 77697 | 108514 | 53162762 |
Musculoskeletal stiffness | 15.82 | 10.17 | 110 | 77680 | 123258 | 53148018 |
Uterine perforation | 15.76 | 10.17 | 34 | 77756 | 7385 | 53263891 |
Differential white blood cell count abnormal | 15.62 | 10.17 | 11 | 77779 | 729 | 53270547 |
Blastocystis infection | 15.52 | 10.17 | 4 | 77786 | 17 | 53271259 |
Product use in unapproved indication | 15.46 | 10.17 | 98 | 77692 | 112191 | 53159085 |
Paranoia | 15.40 | 10.17 | 44 | 77746 | 11380 | 53259896 |
Cough | 15.29 | 10.17 | 273 | 77517 | 256620 | 53014656 |
Dyspnoea | 14.90 | 10.17 | 701 | 77089 | 585531 | 52685745 |
Inflammation | 14.72 | 10.17 | 39 | 77751 | 57097 | 53214179 |
Pneumocystis jirovecii pneumonia | 14.66 | 10.17 | 3 | 77787 | 16375 | 53254901 |
Basal cell carcinoma | 14.60 | 10.17 | 8 | 77782 | 23461 | 53247815 |
Pulmonary embolism | 14.49 | 10.17 | 241 | 77549 | 114201 | 53157075 |
Ureteric stenosis | 14.48 | 10.17 | 10 | 77780 | 642 | 53270634 |
Osteoporosis | 14.15 | 10.17 | 29 | 77761 | 46431 | 53224845 |
Ill-defined disorder | 14.11 | 10.17 | 32 | 77758 | 49412 | 53221864 |
pH body fluid increased | 14.06 | 10.17 | 3 | 77787 | 4 | 53271272 |
Hypoglycaemia | 13.94 | 10.17 | 42 | 77748 | 58971 | 53212305 |
Jaw clicking | 13.85 | 10.17 | 4 | 77786 | 28 | 53271248 |
Sports injury | 13.61 | 10.17 | 4 | 77786 | 30 | 53271246 |
Fear | 13.47 | 10.17 | 54 | 77736 | 16587 | 53254689 |
Attention-seeking behaviour | 13.39 | 10.17 | 5 | 77785 | 84 | 53271192 |
Herpes zoster | 13.31 | 10.17 | 59 | 77731 | 73960 | 53197316 |
Intentional product misuse | 13.30 | 10.17 | 120 | 77670 | 49272 | 53222004 |
Anhedonia | 13.30 | 10.17 | 40 | 77750 | 10647 | 53260629 |
Fallot's tetralogy | 13.02 | 10.17 | 5 | 77785 | 91 | 53271185 |
Ventricular septal defect | 12.97 | 10.17 | 23 | 77767 | 4327 | 53266949 |
Loss of personal independence in daily activities | 12.95 | 10.17 | 55 | 77735 | 69760 | 53201516 |
Interstitial lung disease | 12.95 | 10.17 | 43 | 77747 | 58579 | 53212697 |
Unresponsive to stimuli | 12.74 | 10.17 | 88 | 77702 | 33338 | 53237938 |
Heart rate increased | 12.59 | 10.17 | 179 | 77611 | 82136 | 53189140 |
Base excess increased | 12.51 | 10.17 | 4 | 77786 | 41 | 53271235 |
Vasoplegia syndrome | 12.42 | 10.17 | 12 | 77778 | 1240 | 53270036 |
Osteonecrosis of jaw | 12.39 | 10.17 | 21 | 77769 | 36125 | 53235151 |
Drug dependence | 12.37 | 10.17 | 63 | 77727 | 21409 | 53249867 |
Stomatitis | 12.34 | 10.17 | 88 | 77702 | 98070 | 53173206 |
Aggression | 12.34 | 10.17 | 67 | 77723 | 23336 | 53247940 |
Hepatitis | 12.27 | 10.17 | 19 | 77771 | 33875 | 53237401 |
Water intoxication | 12.19 | 10.17 | 8 | 77782 | 472 | 53270804 |
Thrombocytopenia | 11.92 | 10.17 | 137 | 77653 | 138590 | 53132686 |
Breast cancer | 11.75 | 10.17 | 35 | 77755 | 49323 | 53221953 |
Chronic kidney disease | 11.49 | 10.17 | 105 | 77685 | 43265 | 53228011 |
Pulmonary fibrosis | 11.40 | 10.17 | 11 | 77779 | 24124 | 53247152 |
Fear of disease | 11.39 | 10.17 | 11 | 77779 | 1136 | 53270140 |
Ischaemic stroke | 11.39 | 10.17 | 6 | 77784 | 17987 | 53253289 |
Neuroleptic malignant syndrome | 11.35 | 10.17 | 41 | 77749 | 11992 | 53259284 |
Infusion site macule | 11.24 | 10.17 | 3 | 77787 | 15 | 53271261 |
Intestinal ischaemia | 11.21 | 10.17 | 30 | 77760 | 7472 | 53263804 |
Finger amputation | 11.20 | 10.17 | 8 | 77782 | 542 | 53270734 |
Small intestinal obstruction | 11.09 | 10.17 | 52 | 77738 | 17095 | 53254181 |
Prolonged rupture of membranes | 10.95 | 10.17 | 4 | 77786 | 63 | 53271213 |
Thinking abnormal | 10.95 | 10.17 | 37 | 77753 | 10471 | 53260805 |
Jugular vein thrombosis | 10.94 | 10.17 | 17 | 77773 | 2869 | 53268407 |
Acute lung injury | 10.88 | 10.17 | 12 | 77778 | 1449 | 53269827 |
Injection site erythema | 10.85 | 10.17 | 67 | 77723 | 77182 | 53194094 |
Hypophagia | 10.81 | 10.17 | 80 | 77710 | 30982 | 53240294 |
Neonatal tachycardia | 10.65 | 10.17 | 3 | 77787 | 19 | 53271257 |
Hyperkinetic heart syndrome | 10.65 | 10.17 | 3 | 77787 | 19 | 53271257 |
Skin ulcer | 10.62 | 10.17 | 23 | 77767 | 36096 | 53235180 |
Intestinal obstruction | 10.57 | 10.17 | 75 | 77715 | 28666 | 53242610 |
Retroplacental haematoma | 10.56 | 10.17 | 5 | 77785 | 155 | 53271121 |
Arm amputation | 10.52 | 10.17 | 3 | 77787 | 20 | 53271256 |
Heart rate decreased | 10.47 | 10.17 | 24 | 77766 | 36923 | 53234353 |
Lentigo | 10.46 | 10.17 | 6 | 77784 | 278 | 53270998 |
Retching | 10.32 | 10.17 | 44 | 77746 | 13889 | 53257387 |
Bradycardia | 10.31 | 10.17 | 61 | 77729 | 70995 | 53200281 |
Tremor | 10.28 | 10.17 | 248 | 77542 | 125488 | 53145788 |
Disorientation | 10.28 | 10.17 | 95 | 77695 | 39264 | 53232012 |
Respiratory rate decreased | 10.23 | 10.17 | 18 | 77772 | 3366 | 53267910 |
Femur fracture | 10.21 | 10.17 | 27 | 77763 | 39558 | 53231718 |
Therapy non-responder | 10.19 | 10.17 | 37 | 77753 | 49083 | 53222193 |
Knee arthroplasty | 10.18 | 10.17 | 21 | 77769 | 33548 | 53237728 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intentional self-injury | 1967.93 | 11.16 | 666 | 30101 | 13234 | 32469525 |
Intentional overdose | 1549.74 | 11.16 | 764 | 30003 | 40837 | 32441922 |
Akathisia | 146.07 | 11.16 | 88 | 30679 | 6937 | 32475822 |
Depressed level of consciousness | 104.76 | 11.16 | 159 | 30608 | 40688 | 32442071 |
Neuroleptic malignant syndrome | 87.64 | 11.16 | 95 | 30672 | 17400 | 32465359 |
Tachycardia | 83.89 | 11.16 | 212 | 30555 | 78876 | 32403883 |
Agitation | 68.75 | 11.16 | 161 | 30606 | 57075 | 32425684 |
Respiratory arrest | 66.40 | 11.16 | 107 | 30660 | 28801 | 32453958 |
Nausea | 64.18 | 11.16 | 520 | 30247 | 320329 | 32162430 |
Vomiting | 63.96 | 11.16 | 411 | 30356 | 235146 | 32247613 |
Sinus tachycardia | 63.47 | 11.16 | 78 | 30689 | 16336 | 32466423 |
Somnolence | 61.66 | 11.16 | 227 | 30540 | 103570 | 32379189 |
Drug ineffective | 60.10 | 11.16 | 176 | 30591 | 383301 | 32099458 |
Off label use | 59.33 | 11.16 | 126 | 30641 | 306194 | 32176565 |
Mydriasis | 59.23 | 11.16 | 49 | 30718 | 6397 | 32476362 |
Toxicity to various agents | 54.14 | 11.16 | 320 | 30447 | 177721 | 32305038 |
Poisoning | 49.70 | 11.16 | 57 | 30710 | 11101 | 32471658 |
Product counterfeit | 41.99 | 11.16 | 13 | 30754 | 190 | 32482569 |
Drug abuse | 40.69 | 11.16 | 167 | 30600 | 80076 | 32402683 |
Overdose | 39.35 | 11.16 | 175 | 30592 | 86902 | 32395857 |
Lethargy | 38.04 | 11.16 | 105 | 30662 | 41123 | 32441636 |
Exposure during pregnancy | 37.53 | 11.16 | 45 | 30722 | 9184 | 32473575 |
Dysarthria | 35.15 | 11.16 | 89 | 30678 | 33112 | 32449647 |
Hallucination | 31.97 | 11.16 | 116 | 30651 | 52503 | 32430256 |
Dystonia | 31.03 | 11.16 | 44 | 30723 | 10579 | 32472180 |
Loss of consciousness | 30.66 | 11.16 | 157 | 30610 | 82550 | 32400209 |
Cardio-respiratory arrest | 30.35 | 11.16 | 119 | 30648 | 55870 | 32426889 |
Consciousness fluctuating | 29.04 | 11.16 | 16 | 30751 | 1064 | 32481695 |
Anxiety | 26.23 | 11.16 | 168 | 30599 | 95837 | 32386922 |
Dehydration | 25.61 | 11.16 | 209 | 30558 | 128749 | 32354010 |
Interstitial lung disease | 25.38 | 11.16 | 15 | 30752 | 64986 | 32417773 |
Dextrocardia | 25.23 | 11.16 | 8 | 30759 | 127 | 32482632 |
General physical health deterioration | 25.19 | 11.16 | 44 | 30723 | 115215 | 32367544 |
Completed suicide | 24.72 | 11.16 | 161 | 30606 | 92356 | 32390403 |
Serotonin syndrome | 24.27 | 11.16 | 55 | 30712 | 19062 | 32463697 |
Pyomyositis | 24.09 | 11.16 | 8 | 30759 | 148 | 32482611 |
Foetal alcohol syndrome | 24.09 | 11.16 | 8 | 30759 | 148 | 32482611 |
Acute kidney injury | 23.49 | 11.16 | 172 | 30595 | 293296 | 32189463 |
Renal impairment | 22.08 | 11.16 | 33 | 30734 | 91939 | 32390820 |
Atrial septal defect | 21.87 | 11.16 | 30 | 30737 | 6995 | 32475764 |
Failure to thrive | 21.83 | 11.16 | 33 | 30734 | 8402 | 32474357 |
Exposure via ingestion | 21.82 | 11.16 | 18 | 30749 | 2339 | 32480420 |
Opisthotonus | 21.72 | 11.16 | 10 | 30757 | 453 | 32482306 |
Suicide attempt | 21.30 | 11.16 | 82 | 30685 | 38162 | 32444597 |
Sedation | 21.01 | 11.16 | 51 | 30716 | 18475 | 32464284 |
General symptom | 20.70 | 11.16 | 12 | 30755 | 880 | 32481879 |
Paralysis | 20.22 | 11.16 | 27 | 30740 | 6136 | 32476623 |
Foetal exposure during pregnancy | 20.16 | 11.16 | 85 | 30682 | 41216 | 32441543 |
Hepatic ischaemia | 19.73 | 11.16 | 9 | 30758 | 399 | 32482360 |
Breathing-related sleep disorder | 18.92 | 11.16 | 7 | 30760 | 180 | 32482579 |
Confusional state | 18.53 | 11.16 | 212 | 30555 | 142903 | 32339856 |
Drug withdrawal syndrome neonatal | 17.22 | 11.16 | 19 | 30748 | 3545 | 32479214 |
Therapeutic product effect incomplete | 16.91 | 11.16 | 9 | 30758 | 41332 | 32441427 |
Pupil fixed | 16.85 | 11.16 | 14 | 30753 | 1837 | 32480922 |
Respiratory depression | 16.76 | 11.16 | 38 | 30729 | 13173 | 32469586 |
Rheumatoid arthritis | 16.39 | 11.16 | 11 | 30756 | 44533 | 32438226 |
Angioedema | 16.22 | 11.16 | 7 | 30760 | 36282 | 32446477 |
Drug withdrawal syndrome | 16.21 | 11.16 | 49 | 30718 | 20182 | 32462577 |
Psychomotor hyperactivity | 16.21 | 11.16 | 30 | 30737 | 9009 | 32473750 |
Conduction disorder | 15.97 | 11.16 | 14 | 30753 | 1976 | 32480783 |
Obsessive thoughts | 15.25 | 11.16 | 9 | 30758 | 682 | 32482077 |
Red blood cells urine positive | 15.22 | 11.16 | 13 | 30754 | 1773 | 32480986 |
Cardiac arrest | 15.16 | 11.16 | 149 | 30618 | 96627 | 32386132 |
Patent ductus arteriosus | 15.00 | 11.16 | 17 | 30750 | 3268 | 32479491 |
Fallot's tetralogy | 14.90 | 11.16 | 6 | 30761 | 195 | 32482564 |
Inappropriate schedule of product administration | 14.72 | 11.16 | 13 | 30754 | 45812 | 32436947 |
Condition aggravated | 14.55 | 11.16 | 87 | 30680 | 155574 | 32327185 |
Unresponsive to stimuli | 14.40 | 11.16 | 58 | 30709 | 27551 | 32455208 |
Skin swelling | 14.14 | 11.16 | 10 | 30757 | 1034 | 32481725 |
Snoring | 14.11 | 11.16 | 16 | 30751 | 3077 | 32479682 |
Drug hypersensitivity | 14.03 | 11.16 | 118 | 30649 | 73282 | 32409477 |
Fatigue | 13.95 | 11.16 | 432 | 30335 | 350269 | 32132490 |
Upper respiratory tract irritation | 13.88 | 11.16 | 4 | 30763 | 45 | 32482714 |
Incision site pain | 13.74 | 11.16 | 13 | 30754 | 2024 | 32480735 |
Psoriasis | 13.74 | 11.16 | 14 | 30753 | 46109 | 32436650 |
Linear IgA disease | 13.68 | 11.16 | 12 | 30755 | 1696 | 32481063 |
Product use in unapproved indication | 13.58 | 11.16 | 40 | 30727 | 87164 | 32395595 |
Cardiomegaly | 13.51 | 11.16 | 38 | 30729 | 15033 | 32467726 |
Environmental exposure | 13.35 | 11.16 | 6 | 30761 | 257 | 32482502 |
Protein urine present | 13.27 | 11.16 | 20 | 30747 | 5077 | 32477682 |
Poor quality product administered | 13.24 | 11.16 | 12 | 30755 | 1769 | 32480990 |
Foetal death | 13.24 | 11.16 | 6 | 30761 | 262 | 32482497 |
Hyperkalaemia | 13.18 | 11.16 | 29 | 30738 | 69721 | 32413038 |
Myocardial infarction | 12.96 | 11.16 | 68 | 30699 | 125608 | 32357151 |
Accidental overdose | 12.91 | 11.16 | 44 | 30723 | 19295 | 32463464 |
Hepatocellular injury | 12.80 | 11.16 | 4 | 30763 | 25314 | 32457445 |
Drug resistance | 12.80 | 11.16 | 3 | 30764 | 22962 | 32459797 |
Restlessness | 12.76 | 11.16 | 52 | 30715 | 24829 | 32457930 |
Treatment failure | 12.71 | 11.16 | 11 | 30756 | 39152 | 32443607 |
Psychotic disorder | 12.52 | 11.16 | 49 | 30718 | 22971 | 32459788 |
Cholestasis | 12.43 | 11.16 | 5 | 30762 | 27028 | 32455731 |
Acute chest syndrome | 12.28 | 11.16 | 6 | 30761 | 311 | 32482448 |
Drug interaction | 12.15 | 11.16 | 140 | 30627 | 218045 | 32264714 |
Tardive dyskinesia | 12.05 | 11.16 | 20 | 30747 | 5511 | 32477248 |
Aggression | 12.05 | 11.16 | 71 | 30696 | 39318 | 32443441 |
Small for dates baby | 11.34 | 11.16 | 15 | 30752 | 3378 | 32479381 |
Source | Code | Description |
---|---|---|
ATC | D04AA10 | DERMATOLOGICALS ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. Antihistamines for topical use |
ATC | R06AD02 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives |
ATC | R06AD52 | RESPIRATORY SYSTEM ANTIHISTAMINES FOR SYSTEMIC USE ANTIHISTAMINES FOR SYSTEMIC USE Phenothiazine derivatives |
ATC | V03AB05 | VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Antidotes |
FDA CS | M0016525 | Phenothiazines |
MeSH PA | D018926 | Anti-Allergic Agents |
MeSH PA | D000982 | Antipruritics |
MeSH PA | D003879 | Dermatologic Agents |
MeSH PA | D018494 | Histamine Agents |
MeSH PA | D006633 | Histamine Antagonists |
MeSH PA | D006634 | Histamine H1 Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
CHEBI has role | CHEBI:35717 | sedatives |
CHEBI has role | CHEBI:36333 | local anaesthetics |
CHEBI has role | CHEBI:37955 | H1-receptor blockers |
CHEBI has role | CHEBI:50857 | anti-allergic agents |
CHEBI has role | CHEBI:50919 | antiemetico |
CHEBI has role | CHEBI:59683 | anti-itching drug |
CHEBI has role | CHEBI:149553 | anti-coronaviral agents |
CHEBI has role | CHEBI:176497 | anti-aging drugs |
FDA EPC | N0000175746 | Phenothiazine |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Vasomotor rhinitis | indication | 8229003 | DOID:4730 |
Nausea and vomiting | indication | 16932000 | |
General anesthesia | indication | 50697003 | |
Sedation | indication | 72641008 | |
Urticaria | indication | 126485001 | |
Seasonal allergic rhinitis | indication | 367498001 | |
Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.19 | Basic |
pKa2 | 3.55 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Histamine H1 receptor | GPCR | ANTAGONIST | Ki | 9.62 | WOMBAT-PK | CHEMBL | |||
D(2) dopamine receptor | GPCR | Ki | 6.61 | WOMBAT-PK | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.59 | DRUG MATRIX | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.92 | DRUG MATRIX | |||||
Sodium-dependent serotonin transporter | Transporter | IC50 | 5.12 | CHEMBL | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.38 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.83 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 6.77 | WOMBAT-PK | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 7.37 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 8.19 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.95 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | WOMBAT-PK | |||||||
Alpha-2B adrenergic receptor | GPCR | Ki | 7.62 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.72 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.94 | DRUG MATRIX | |||||
Histamine H4 receptor | GPCR | Ki | 6.82 | WOMBAT-PK | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8.48 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.92 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 8.38 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 8.98 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 8.48 | DRUG MATRIX | |||||
Aldehyde oxidase | Enzyme | IC50 | 6.29 | WOMBAT-PK | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 6.45 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | Ki | 5.42 | WOMBAT-PK | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 7.50 | DRUG MATRIX | |||||
Cholinesterase | Enzyme | Ki | 7.10 | WOMBAT-PK | |||||
Major prion protein | Surface antigen | EC50 | 5.10 | CHEMBL | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.45 | CHEMBL | |||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 5.16 | CHEMBL | |||||
FAD-linked sulfhydryl oxidase ALR | Enzyme | AC50 | 6.44 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.86 | DRUG MATRIX | |||||
Calmodulin-1 | Cytosolic other | IC50 | 4.22 | CHEMBL | |||||
Alpha-1B adrenergic receptor | GPCR | Ki | 7.68 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 7.10 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 5.59 | CHEMBL | |||||
Pleiotropic ABC efflux transporter of multiple drugs | Transporter | IC50 | 4.75 | CHEMBL | |||||
Chloroquine resistance transporter | Transporter | IC50 | 4.07 | CHEMBL | |||||
Calmodulin | Cytosolic other | Kd | 4.30 | CHEMBL |
ID | Source |
---|---|
4019910 | VUID |
N0000147995 | NUI |
D00480 | KEGG_DRUG |
58-33-3 | SECONDARY_CAS_RN |
4017846 | VANDF |
4019910 | VANDF |
C0033405 | UMLSCUI |
CHEBI:8461 | CHEBI |
CHEMBL1200750 | ChEMBL_ID |
CHEMBL251904 | ChEMBL_ID |
CHEMBL643 | ChEMBL_ID |
DB01069 | DRUGBANK_ID |
D011398 | MESH_DESCRIPTOR_UI |
4927 | PUBCHEM_CID |
7282 | IUPHAR_LIGAND_ID |
516 | INN_ID |
FF28EJQ494 | UNII |
142445 | RXNORM |
2141 | MMSL |
5367 | MMSL |
d00787 | MMSL |
001483 | NDDF |
004459 | NDDF |
14905007 | SNOMEDCT_US |
372871004 | SNOMEDCT_US |
8372007 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0121-0547 | SYRUP | 6.25 mg | ORAL | ANDA | 30 sections |
Promethazine VC with Codeine Oral Solution | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0121-0925 | SOLUTION | 6.25 mg | ORAL | ANDA | 29 sections |
Promethazine VC | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0121-0926 | SOLUTION | 6.25 mg | ORAL | ANDA | 25 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-0927 | SOLUTION | 6.25 mg | ORAL | ANDA | 25 sections |
Promethazine with Codeine | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0121-0928 | SOLUTION | 6.25 mg | ORAL | ANDA | 29 sections |
PROMETHAZINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9940 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 12 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9941 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 12 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9942 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 12 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-5195 | TABLET | 25 mg | ORAL | ANDA | 11 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-8195 | TABLET | 25 mg | ORAL | ANDA | 12 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5307 | TABLET | 25 mg | ORAL | ANDA | 24 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-5319 | TABLET | 50 mg | ORAL | ANDA | 24 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8154 | TABLET | 25 mg | ORAL | ANDA | 21 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-0928 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 25 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-0929 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-0948 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 25 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-0949 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-0955 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 25 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-0956 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-1495 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 25 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-1496 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
PHENERGAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6082 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 25 sections |
PHENERGAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6083 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 25 sections |
PHENERGAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6084 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 26 sections |
PHENERGAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6085 | INJECTION | 50 mg | INTRAMUSCULAR | ANDA | 26 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6099 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 26 sections |
Promethazine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6208 | INJECTION | 25 mg | INTRAMUSCULAR | ANDA | 25 sections |
PROMETHEGAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0132 | SUPPOSITORY | 50 mg | RECTAL | ANDA | 21 sections |
PROMETHEGAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0526 | SUPPOSITORY | 25 mg | RECTAL | ANDA | 21 sections |
PROMETHEGAN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0536 | SUPPOSITORY | 12.50 mg | RECTAL | ANDA | 21 sections |